Furthermore, humans with alterations in the gene encoding SGLT1 resulting in production of functionally limited transporter (resembling pharmacological SGLT1 inhibition) are protected from the development of HF, and all-cause death is significantly lower as compared with non-affected subjects23. The gene discussed is SLC5A1; the disease is hydrops fetalis.